U.S. Markets closed

Cytosorbents Corporation (CTSO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.63-0.18 (-2.30%)
At close: 4:00PM EDT
7.63 0.00 (0.00%)
After hours: 05:12PM EDT

Cytosorbents Corporation

7 Deer Park Drive
Suite K
Monmouth Junction, NJ 08852
United States
732 329 8885
http://www.cytosorbents.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees195

Key Executives

NameTitlePayExercisedYear Born
Dr. Phillip P. ChanCEO & Director728.08k83.75k1970
Mr. Vincent J. Capponi M.S., MSPres & COO597.21k158.08k1958
Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPACFO & Sec.487.85k60.53k1955
Dr. Efthymios N. Deliargyris M.D., FACC, FESC, FSCAIChief Medical Officer490.11kN/A1968
Dr. Christian Steiner M.D.Exec. VP of Sales & MarketingN/AN/AN/A
Mr. Christopher CramerVP of Bus. Devel.N/AN/AN/A
Dr. Robert H. BartlettCo-Chairman of Cardiac Surgery Advisory Board & ConsultantN/AN/A1939
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey.

Corporate Governance

Cytosorbents Corporation’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.